Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 23rd Annual Global Healthcare

Michael Ulz
Equity Analyst

All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I’m Mike Ulz, one of the biotech analysts here, and it’s my pleasure to introduce Brian Lian, CEO from Viking Therapeutics. Before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, maybe, Brian, I’ll just hand it over to you to make some introductory comments for people that might not be familiar with your story.

Brian Lian
President, CEO & Director

Sure, sure. Thanks, Mike. Thanks to Morgan Stanley also for the invitation. I appreciate the schedule and really a great list of investors to meet with. So yes, I’m Brian Lian, CEO of Viking. We have a lot going on at the company. We have today, 2 Phase III trials ongoing in obesity. Those were initiated in the second quarter, seem to be enrolling well so far and looking forward to completing the enrollment and then executing those studies through the next 78 weeks of treatment period following the completion of enrollment.

We recently read out a Phase IIa trial, 13-week study with an oral formulation of the same compound that’s in Phase III. This was a 13-week daily dosing study, which showed up to 12% weight loss at 13 weeks, which we’re really, really happy about, good tolerability. And the next step with the oral program would be to hopefully schedule an end of